https://www.delveinsight.com/blog/pharma-happenings-for-biogen-pfizer-viiv-calliditas/
-
Pfizer’s COVID-19 vaccine heralded as the showstopper with over 90% effectiveness
-
Calliditas unfolded positive late-stage study results from the pivotal phase 3 NefIgArd trial
-
ViiV’s long-acting drug Cabotegravir trumps Gilead’s Truvada in beating HIV in women
-
Hopes to get an Alzheimer’s drug dims after the FDA advisers reject Biogen’s Aducanumab